Cargando…

The Parasite Reduction Ratio (PRR) Assay Version 2: Standardized Assessment of Plasmodium falciparum Viability after Antimalarial Treatment In Vitro

With artemisinin-resistant Plasmodium falciparum parasites emerging in Africa, the need for new antimalarial chemotypes is persistently high. The ideal pharmacodynamic parameters of a candidate drug are a rapid onset of action and a fast rate of parasite killing or clearance. To determine these para...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walz, Annabelle, Duffey, Maëlle, Aljayyoussi, Ghaith, Sax, Sibylle, Leroy, Didier, Besson, Dominique, Burrows, Jeremy N., Cherkaoui-Rbati, Mohammed H., Gobeau, Nathalie, Westwood, Marie-Anne, Siethoff, Christoph, Gamo, Francisco-Javier, Mäser, Pascal, Wittlin, Sergio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959027/ https://www.ncbi.nlm.nih.gov/pubmed/37009844 http://dx.doi.org/10.3390/ph16020163

Ejemplares similares

Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment
por: Radohery, Georges F. R., et al.
Publicado: (2022)

New In Vitro Interaction-Parasite Reduction Ratio Assay for Early Derisk in Clinical Development of Antimalarial Combinations
por: Wicha, Sebastian G., et al.
Publicado: (2022)

Anti-malarial ozonides OZ439 and OZ609 tested at clinically relevant compound exposure parameters in a novel ring-stage survival assay
por: Walz, Annabelle, et al.
Publicado: (2019)

Ex vivo susceptibility to new antimalarial agents differs among human-infecting Plasmodium species
por: van Schalkwyk, Donelly A., et al.
Publicado: (2021)

Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development
por: Burgert, Lydia, et al.
Publicado: (2020)

A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048
por: McCarthy, James S, et al.
Publicado: (2020)

Monoclonal Antibodies That Recognize the Alkylation Signature of Antimalarial Ozonides OZ277 (Arterolane) and OZ439 (Artefenomel)
por: Jourdan, Joëlle, et al.
Publicado: (2015)

First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials
por: Moehrle, Joerg J, et al.
Publicado: (2013)

The harms of police frisking in times of a pandemic
por: Aljayyoussi, Ghaith
Publicado: (2020)

Parasite-Host Dynamics throughout Antimalarial Drug Development Stages Complicate the Translation of Parasite Clearance
por: Burgert, Lydia, et al.
Publicado: (2021)

Phenotypic Screens, Chemical Genomics, and Antimalarial Lead Discovery
por: Garcia-Bustos, Jose F., et al.
Publicado: (2011)

A pharmacokinetic–pharmacodynamic model for chemoprotective agents against malaria
por: Cherkaoui‐Rbati, Mohammed H., et al.
Publicado: (2022)

SARS-CoV-2 viability on sports equipment is limited, and dependent on material composition
por: Edwards, Thomas, et al.
Publicado: (2022)

The Activities of Current Antimalarial Drugs on the Life Cycle Stages of Plasmodium: A Comparative Study with Human and Rodent Parasites
por: Delves, Michael, et al.
Publicado: (2012)

Pseudo-Response Regulator (PRR) Homologues of the Moss Physcomitrella patens: Insights into the Evolution of the PRR Family in Land Plants
por: Satbhai, Santosh B., et al.
Publicado: (2011)

In vitro and in vivo characterization of the antimalarial lead compound SSJ-183 in Plasmodium models
por: Schleiferböck, Sarah, et al.
Publicado: (2013)

Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of UCB7362
por: Lowe, Martin A., et al.
Publicado: (2022)

P. falciparum In Vitro Killing Rates Allow to Discriminate between Different Antimalarial Mode-of-Action
por: Sanz, Laura M., et al.
Publicado: (2012)

Susceptibility of Ugandan Plasmodium falciparum Isolates to the Antimalarial Drug Pipeline
por: Kreutzfeld, Oriana, et al.
Publicado: (2023)

Antimalarial drug discovery – the path towards eradication
por: BURROWS, JEREMY N, et al.
Publicado: (2014)

Cancer: A Tale of Aberrant PRR Response
por: Nagi, Raunaq Singh, et al.
Publicado: (2014)

Predicting Optimal Antimalarial Drug Combinations from a Standardized Plasmodium falciparum Humanized Mouse Model
por: Demarta-Gatsi, Claudia, et al.
Publicado: (2023)

Targeting Pattern Recognition Receptors (PRR) for Vaccine Adjuvantation: From Synthetic PRR Agonists to the Potential of Defective Interfering Particles of Viruses
por: Vasou, Andri, et al.
Publicado: (2017)

Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials
por: Norcross, Neil R., et al.
Publicado: (2016)

How to tackle antimalarial resistance?
por: Leroy, Didier
Publicado: (2016)

Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study
por: Chughlay, Mohamed Farouk, et al.
Publicado: (2021)

Discovering antimalarials with a differential mode of action
por: Sanz, Laura, et al.
Publicado: (2014)

Development and application of a PBPK modeling strategy to support antimalarial drug development
por: Abla, Nada, et al.
Publicado: (2023)

Ancient Chinese Methods Are Remarkably Effective for the Preparation of Artemisinin-Rich Extracts of Qing Hao with Potent Antimalarial Activity
por: Wright, Colin W., et al.
Publicado: (2010)

Discovery of a novel target for cancer: PRR14
por: Xiao, Shaowen, et al.
Publicado: (2016)

PRR11 in Malignancies: Biological Activities and Targeted Therapies
por: Han, Wei, et al.
Publicado: (2022)

Profiling of the anti-malarial drug candidate SC83288 against artemisinins in Plasmodium falciparum
por: Duffey, Maëlle, et al.
Publicado: (2018)

Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose–Efficacy Modeling
por: Le Bihan, Amélie, et al.
Publicado: (2016)

Determinants of eukaryal cell killing by the bacterial ribotoxin PrrC
por: Meineke, Birthe, et al.
Publicado: (2011)

A novel role of PRR14 in the regulation of skeletal myogenesis
por: Yang, M, et al.
Publicado: (2015)

Intracellular PD Modelling (PD(i)) for the Prediction of Clinical Activity of Increased Rifampicin Dosing
por: Aljayyoussi, Ghaith, et al.
Publicado: (2019)

OptiMal-PK: an internet-based, user-friendly interface for the mathematical-based design of optimized anti-malarial treatment regimens
por: Aljayyoussi, Ghaith, et al.
Publicado: (2016)

Retrospective Analysis Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation Offers Improvements in Efficiency of the Design of Volunteer Infection Studies for Antimalarial Drug Development
por: Andrews, Kayla Ann, et al.
Publicado: (2020)

Antimalarial drug discovery: progress and approaches
por: Siqueira-Neto, Jair L, et al.
Publicado: (2023)

Isoxazolopyrimidine-Based Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase with Antimalarial Activity
por: Kokkonda, Sreekanth, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_p0efse8gp1ufqq36h3uj3s5klg